New Biopharma Breakthrough : GSK and Hengrui’s Partnership Forging
Global Therapeutic Pathways

PharmaGenDrx News Bureau – 31st July,2025

10:30 AM IST

GSK has entered into a strategic alliance with Hengrui Pharma to jointly develop up to twelve innovative therapies, with the goal of enhancing GSK’s upcoming therapeutic waves across significant therapeutic areas such as respiratory, immunology, inflammation and oncology. This collaboration elevates Hengrui Pharma’s global footprint and market presence. Currently under clinical development HRS-9821 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) supports GSK to treat a broad spectrum of patients suffering from dyspnea and individuals who are less likely to receive corticosteroid or biologics due to disease profile.

GSK is set to make an initial payment of $500 million under the terms of the said agreement, aiding the development of these programmes through the completion of the Phase I clinical trial.

Tony Wood’s statement, Chief Scientific Officer, R&D, GSK reflects the potential bond between GSK and Hengrui Pharma. This agreement highlights the GSK’s existing pipeline and also focuses on the strategies to meet the targets and reach the zenith of success with advanced assets for patient impact.

The total potential value of the agreement is estimated at up to $12 billion, subject to the achievement of predefined development and commercial milestones.

By Sweta Nandi